RS61709B1 - Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za lečenje šizofrenije - Google Patents

Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za lečenje šizofrenije

Info

Publication number
RS61709B1
RS61709B1 RS20210433A RSP20210433A RS61709B1 RS 61709 B1 RS61709 B1 RS 61709B1 RS 20210433 A RS20210433 A RS 20210433A RS P20210433 A RSP20210433 A RS P20210433A RS 61709 B1 RS61709 B1 RS 61709B1
Authority
RS
Serbia
Prior art keywords
temperature
mixture
aripiprazole
surface area
crystallized particles
Prior art date
Application number
RS20210433A
Other languages
English (en)
Serbian (sr)
Inventor
Wilfredo Morales Jr
Tarek A Zeidan
Renato A Chiarella
Steven G Wright
Jason M Perry
Original Assignee
Alkermes Pharma Ireland Ltd
Wilfredo Morales Jr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd, Wilfredo Morales Jr filed Critical Alkermes Pharma Ireland Ltd
Publication of RS61709B1 publication Critical patent/RS61709B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
RS20210433A 2014-08-25 2015-08-24 Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za lečenje šizofrenije RS61709B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462041341P 2014-08-25 2014-08-25
PCT/US2015/046525 WO2016032950A1 (en) 2014-08-25 2015-08-24 Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
EP15836431.5A EP3185867B1 (en) 2014-08-25 2015-08-24 Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia

Publications (1)

Publication Number Publication Date
RS61709B1 true RS61709B1 (sr) 2021-05-31

Family

ID=55347322

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210433A RS61709B1 (sr) 2014-08-25 2015-08-24 Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za lečenje šizofrenije

Country Status (20)

Country Link
US (5) US10064859B2 (enExample)
EP (2) EP3865476B1 (enExample)
JP (2) JP6591546B2 (enExample)
CN (2) CN111454207B (enExample)
AU (2) AU2015306910B2 (enExample)
CA (1) CA2959329C (enExample)
CY (1) CY1124058T1 (enExample)
DK (1) DK3185867T3 (enExample)
ES (2) ES2862098T3 (enExample)
HR (1) HRP20210551T1 (enExample)
HU (1) HUE054641T2 (enExample)
IL (1) IL250661B (enExample)
LT (1) LT3185867T (enExample)
MA (2) MA55917A (enExample)
PL (1) PL3185867T3 (enExample)
PT (1) PT3185867T (enExample)
RS (1) RS61709B1 (enExample)
SI (1) SI3185867T1 (enExample)
SM (1) SMT202100212T1 (enExample)
WO (1) WO2016032950A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013349388B2 (en) 2012-09-19 2018-06-28 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
EP3865476B1 (en) * 2014-08-25 2024-08-14 Alkermes Pharma Ireland Limited Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
WO2016181406A1 (en) * 2015-05-08 2016-11-17 Davuluri Ramamohan Rao Improved process for the preparation of aripiprazole with reduced particle size
WO2018104953A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate
CN111315722B (zh) 2017-07-28 2023-06-16 因特奎姆私人控股公司 制备月桂酰阿立哌唑的方法
CN110218209B (zh) * 2018-03-02 2022-09-30 上海现代药物制剂工程研究中心有限公司 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN113105389B (zh) * 2021-04-16 2022-04-08 江苏海洋大学 一种阿立哌唑药物共晶及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
ES2315721T5 (es) * 2003-10-23 2012-08-24 Otsuka Pharmaceutical Co., Ltd. Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
SI2234617T2 (sl) 2007-12-19 2025-05-30 Janssen Pharmaceutica Nv Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje
US20110003823A1 (en) 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
HUE033442T2 (en) * 2009-06-25 2017-11-28 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2012077134A1 (en) * 2010-12-07 2012-06-14 Ind-Swift Laboratories Limted Process for preparing aripiprazole polymorphs
BR112013017506B1 (pt) * 2011-01-07 2021-01-26 Neodyne Biosciences, Inc. montagem de curativo
DK2685979T3 (da) * 2011-03-18 2016-12-19 Alkermes Pharma Ireland Ltd Injicerbare farmaceutiske sammensætninger, omfattende et vand-uopløseligt, antipsykotisk sorbitanlaurat og polysorbat 20.
ES2765036T3 (es) * 2012-03-19 2020-06-05 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden esteres de ácidos grasos
AU2013349388B2 (en) * 2012-09-19 2018-06-28 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
EP3865476B1 (en) * 2014-08-25 2024-08-14 Alkermes Pharma Ireland Limited Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia

Also Published As

Publication number Publication date
ES2862098T3 (es) 2021-10-07
EP3185867A4 (en) 2018-01-24
LT3185867T (lt) 2021-06-10
ES2994850T3 (en) 2025-02-03
AU2020264303B2 (en) 2022-10-13
JP2019210296A (ja) 2019-12-12
IL250661A0 (en) 2017-04-30
CY1124058T1 (el) 2022-05-27
MA40480B1 (fr) 2021-08-31
CN111454207B (zh) 2024-10-18
SI3185867T1 (sl) 2021-08-31
PT3185867T (pt) 2021-04-12
HRP20210551T1 (hr) 2021-08-20
US20210205302A1 (en) 2021-07-08
AU2015306910A8 (en) 2020-11-19
CA2959329C (en) 2023-06-27
JP6591546B2 (ja) 2019-10-16
PL3185867T3 (pl) 2021-11-22
AU2015306910B2 (en) 2020-11-19
CN107106556B (zh) 2020-06-05
EP3185867A1 (en) 2017-07-05
DK3185867T3 (da) 2021-03-15
US11883394B2 (en) 2024-01-30
HUE054641T2 (hu) 2021-09-28
NZ729479A (en) 2021-03-26
CA2959329A1 (en) 2016-03-03
US10478434B2 (en) 2019-11-19
CN107106556A (zh) 2017-08-29
US20160051546A1 (en) 2016-02-25
WO2016032950A1 (en) 2016-03-03
EP3865476B1 (en) 2024-08-14
CN111454207A (zh) 2020-07-28
EP3865476A1 (en) 2021-08-18
US20190015408A1 (en) 2019-01-17
MA55917A (fr) 2022-03-16
US20240245676A1 (en) 2024-07-25
SMT202100212T1 (it) 2021-07-12
JP2017526747A (ja) 2017-09-14
AU2015306910A1 (en) 2017-03-16
IL250661B (en) 2020-04-30
US10064859B2 (en) 2018-09-04
EP3185867B1 (en) 2021-01-13
AU2020264303A1 (en) 2020-11-26
US20200108063A1 (en) 2020-04-09
US10973816B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
RS61709B1 (sr) Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za lečenje šizofrenije
JP2007509153A (ja) 所望の平均粒径を有する無菌のアリピプラゾールを製造する方法
CN1646101A (zh) 晶体的制备方法、由该方法得到的晶体和所述晶体在药物制剂中的应用
RS67259B1 (sr) Kompozicije koje aktiviraju piruvat kinazu r (pkr)
BR112019018458A2 (pt) produção de um produto farmacêutico cristalino
US7417044B2 (en) Tadalafil having a large particle size and a process for preparation thereof
CN101163704A (zh) 大粒径他达那非及其制备方法
HK40057525B (en) Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
HK40057525A (en) Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
NZ729479B2 (en) Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
HK1246636A1 (en) Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
HK1246636B (en) Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
EA048358B1 (ru) Кристаллическая форма гетероциклического соединения, способ ее получения и ее применение
HK1090287A (en) Process for production of crystals of a medicinally effective ingredient, crystals obtained thereby and their use in pharmaceutical preparations